We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. CAR T-cell therapy can serve as a frontline treatment ...

Durable responses were seen when axicabtagene ciloleucel (axi-cel; Yescarta) was administered as a first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), according to findings ...

Sattva S. Neelapu, MD, professor and deputy department chair in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses ...

Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen ...

-- ZUMA-12 Results Are First to Support Potential of CAR T in Earlier Lines of Therapy -- “Despite well-established standard treatment regimens in newly diagnosed large B-cell lymphoma, patients with ...

HOUSTON ? A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and ...

Gilead Sciences, Inc.’s GILD Kite announced results from the interim analysis of ZUMA-12, a multicenter, open-label, single-arm phase II study evaluating Yescarta (axicabtagene ciloleucel), a chimeric ...